NEW Post #4114
Q !!Hs1Jq13jV6 5 May 2020 - 12:24:20 PM PST
https://pubmed.ncbi.nlm.nih.gov/16115318/
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30251-8/fulltext
When the protein sequence of the SARS-CoV-2 receptor binding site was analyzed, an interesting result was found. While SARS-CoV-2 is overall more similar to bat coronaviruses, the receptor binding site was more similar to SARS-CoV.
https://www.cell.com/cell/fulltext/S0092-8674(20)30262-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420302622%3Fshowall%3Dtrue
Both SARS-CoV-2 and SARS-CoV use the same host cell receptor. It also found that, for both viruses, the viral proteins used for host cell entry bind to the receptor with the same tightness (affinity).
Knowledge is power.
Q
Engineered mutation.
The hand of man is obvious.
Q
I was trolled for bringing this up on regular fr thread awhile back. But the trails keep coming back around to it. This is one of the few pages that the editor's have not gone back and added notes to to misdirect.
Goes with this: Will SARS come back - connection of Dr. Shi Zhengli and UNC
4/12/2015
Excerpt:
"Recently, Prof. Zhengli Shi and Xingyi Ge from WIV, in cooperation with researchers from University of North Carolina, Harvard Medical School, Bellinzona Institute of Microbiology and etc, examine the disease potential of a SARS-like virus, SHC014-CoV, which is currently circulating in Chinese horseshoe bat populations. Using the SARS-CoV reverse genetics system, the scientists generated and characterized a chimeric virus expressing the spike of bat coronavirus SHC014 in a mouse-adapted SARS-CoV backbone.
The results indicate that group 2b viruses encoding the SHC014 spike in a wild-type backbone can efficiently use multiple orthologs of the SARS receptor human angiotensin converting enzyme II (ACE2), replicate efficiently in primary human airway cells and achieve in vitro titers equivalent to epidemic strains of SARS-CoV. Evaluation of available SARS-based immune-therapeutic and prophylactic modalities revealed poor efficacy; both monoclonal antibody and vaccine approaches failed to neutralize and protect from infection with CoVs using the novel spike protein."